Immune Checkpoint Biology in Health and Disease
- 1st Edition, Volume 382 - January 15, 2024
- Imprint: Academic Press
- Editors: Lorenzo Galluzzi, Abhishek Garg
- Language: English
- Hardback ISBN:9 7 8 - 0 - 4 4 3 - 1 3 5 7 3 - 6
- eBook ISBN:9 7 8 - 0 - 4 4 3 - 1 3 5 7 4 - 3
Immune Checkpoint Biology in Health and Disease, Volume 382 provides in-depth reviews on the latest progress concerning research on immune-checkpoint biology and its immuno… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quoteImmune Checkpoint Biology in Health and Disease, Volume 382 provides in-depth reviews on the latest progress concerning research on immune-checkpoint biology and its immunotherapeutic implications, especially in cancer. Topics connected to immune-checkpoint biology covered in this volume include Novel technologies for applying immune checkpoint blockers, Next-generation deconvolution of transcriptomic data to investigate the tumor microenvironment, Immune checkpoints targeting dendritic cells for antibody-based modulation in cancer, Immune checkpoint biology in health & disease: Immune checkpoint biology and autoimmunity in cancer patients, and much more.
Other sections cover Recent advancements in tumor microenvironment landscaping for target selection and response prediction in immune checkpoint therapies achieved through spatial protein multiplexing analysis, Immune Modulation During Anti-Cancer Radio(immuno)therapy, and Preconditioning with immunogenic cell death-inducing treatments for subsequent immunotherapy.
Other sections cover Recent advancements in tumor microenvironment landscaping for target selection and response prediction in immune checkpoint therapies achieved through spatial protein multiplexing analysis, Immune Modulation During Anti-Cancer Radio(immuno)therapy, and Preconditioning with immunogenic cell death-inducing treatments for subsequent immunotherapy.
- Provides comprehensive reviews from frontline experts on the topic of Immune-checkpoints
- Presents useful schematic material and cutting-edge discussions
- Covers the latest insights and future perspectives on the covered topics and their implications for immunology and immunotherapy, as well as clinical perspectives
Immunologists, Clinicians, Oncologists, Translational researchers, and Technologists involved in immuno-oncology, cancer research, autoimmunity, therapy, omics technologies, inflammation and immunity research
- Cover image
- Series Page
- Title page
- Copyright
- Table of Contents
- Contributors
- Chapter One: Novel technologies for applying immune checkpoint blockers
- Abstract
- 1 Inhibitory immune checkpoints curtail T cell-mediated cancer rejection
- 2 Targeting inhibitory immune checkpoints on T cells
- 3 Inhibitory immune checkpoints: beyond CTLA-4, PD-1 and PD-L1
- 4 Immune checkpoint inhibitors: beyond monoclonal antibodies
- 5 Gene-based delivery to improve immune checkpoint inhibition
- 6 Delivery routes for immune checkpoint therapy
- 7 Emerging drug delivery technologies for immune checkpoint therapy
- 8 Exploiting cells to improve the delivery of immune checkpoint inhibitors: biomimetics
- 9 Translational outlook of novel immune checkpoint inhibitor applications
- 10 Conclusion
- References
- Chapter Two: Next-generation deconvolution of transcriptomic data to investigate the tumor microenvironment
- Abstract
- 1 Introduction
- 2 First-generation methods
- 3 Second-generation methods
- 4 Methods for spatial deconvolution
- 5 Outlook and conclusions
- References
- Chapter Three: Immune checkpoints targeting dendritic cells for antibody-based modulation in cancer
- Abstract
- 1 Introduction
- 2 DC ontogeny and functions
- 3 Candidate targets and currently targeted ICPs expressed by DC
- 4 Concluding remarks
- References
- Chapter Four: Immune checkpoint biology in health & disease: Immune checkpoint biology and autoimmunity in cancer patients
- Abstract
- 1 Introduction
- 2 Immune checkpoints: Physiology and deficiency
- 3 Immune-related adverse events
- 4 Future outlook
- References
- Chapter Five: Recent advancements in tumour microenvironment landscaping for target selection and response prediction in immune checkpoint therapies achieved through spatial protein multiplexing analysis
- Abstract
- 1 Introduction
- 2 Spatial protein multiplexing analysis to characterise the tumour microenvironment
- 3 Spatial protein multiplexing analysis to understand the heterogeneity of tumoural cells
- 4 Spatial protein multiplexing analysis to study the interplay of the immune microenvironment and tumour progression
- 5 Spatial protein multiplexing analysis to discover biomarkers
- 6 Spatial protein multiplexing analysis to suggest new treatment strategies
- 7 Conclusion and future perspectives
- References
- Chapter Six: Immune modulation during anti-cancer radio(immuno)therapy
- Abstract
- 1 Introduction
- 2 Anti-tumour immune responses
- 3 Cancer therapies
- 4 Conclusion
- Acknowledgements
- References
- Chapter Seven: Preconditioning with immunogenic cell death-inducing treatments for subsequent immunotherapy
- Abstract
- 1 Immunotherapy
- 2 Immune-checkpoint inhibitors
- 3 Immunogenic cell death
- 4 Combinatorial approaches
- References
- Edition: 1
- Volume: 382
- Published: January 15, 2024
- No. of pages (Hardback): 560
- No. of pages (eBook): 277
- Imprint: Academic Press
- Language: English
- Hardback ISBN: 9780443135736
- eBook ISBN: 9780443135743
LG
Lorenzo Galluzzi
Lorenzo Galluzzi is Assistant Professor of Cell Biology in Radiation Oncology at the Department of Radiation Oncology of the Weill Cornell Medical College, Honorary Assistant Professor Adjunct with the Department of Dermatology of the Yale School of Medicine, Honorary Associate Professor with the Faculty of Medicine of the University of Paris, and Faculty Member with the Graduate School of Biomedical Sciences and Biotechnology of the University of Ferrara, the Graduate School of Pharmacological Sciences of the University of Padova, and the Graduate School of Network Oncology and Precision Medicine of the University of Rome “La Sapienza”. Moreover, he is Associate Director of the European Academy for Tumor Immunology and Founding Member of the European Research Institute for Integrated Cellular Pathology.
Galluzzi is best known for major experimental and conceptual contributions to the fields of cell death, autophagy, tumor metabolism and tumor immunology. He has published over 450 articles in international peer-reviewed journals and is the Editor-in-Chief of four journals:
OncoImmunology (which he co-founded in 2011), International Review of Cell and Molecular Biology, Methods in Cell biology, and Molecular and Cellular Oncology (which he co-founded in 2013). Additionally, he serves as Founding Editor for Microbial Cell and Cell Stress, and Associate Editor for Cell Death and Disease, Pharmacological Research and iScience.
Affiliations and expertise
Assistant Professor of Cell Biology in Radiation Oncology, Department of Radiation Oncology, Weill Cornell Medical College, NY, USAAG
Abhishek Garg
Prof. Abhishek D. Garg is currently Assistant Professor at Department of Cellular & Molecular Medicine (KU Leuven, Belgium) and head of the Laboratory for Cell Stress & Immunity also at KU Leuven. Dr. Garg did his post-doctoral training at KU Leuven, combined with research visitations at University of Helsinki, Finland, and De Duve Institute, Belgium, after receiving his PhD from KU Leuven. During his PhD-postdoc stints, Dr. Garg played an instrumental role in elucidating novel mechanisms that make cancer cell death immunogenic in the context of anticancer therapy. He worked on uncovering the links between endoplasmic reticulum stress, autophagy, apoptosis/necroptosis, and damage-associated molecular patterns (DAMPs) or danger signals in dying cancer cells. This work resulted in creation of innovative dendritic cell (DC) vaccines against glioblastoma.
His lab focuses on applying novel reverse translational approaches (i.e. human data to pre-clinical validation) to create innovative immunotherapy or biomarker solutions against hard-to-treat immunotherapy resistant tumors and eventually pave way for the forward translation of these solutions toward the clinic. His lab is working closely with oncologists (at home & abroad) for translation toward early-stage clinical trials.
His >100 publications have been cited >20,000 times (h-index >50). He has delivered >40 lectures at various (inter)national conferences or institutional/company seminars. Dr. Garg’s contributions have been recognized by the 41st Prix Galien award for Pharmacological Research (Belgium, 2023), KU Leuven Research Council Award (2016), European Society of Photobiology (ESP) Young Investigator Award (2013), and FWO-McKinsey & Company Scientific Prize (2012).
Read Immune Checkpoint Biology in Health and Disease on ScienceDirect